DRUG AND CARDIAC RESYNCHRONIZATION THERAPY IN THE TREATMENT OF CHRONIC HEART FAILURE (LITERATURE REVIEW)

Б А Ахыт, Н. Г. Ложкина, Salim Berkinbayev, Пашимов Марат Орумбасарович, К М Кошумбаева, Aisulu Mussagaliyeva, Gulnara Junusbekova, Alieva G., Артеменко Сергей Николаевич

2024

Full text Open access: Green Metadata (CSL-JSON)

DOI 10.26787/nydha-2686-6838-2024-26-12-35-45

Data confidence 70 medium

How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

The article deals with the role of pharmacological agents and implantable devices in the treatment of chronic heart failure (CHF) with different ejection fraction: preserved ejection fraction, mildly reduced ejection fraction and reduced ejection fraction (HFpEF, CHFmrEFV, CHFrFV). The authors emphasise that despite the widespread introduction of angiotensin receptor and neprilysin inhibitor (ARNI), beta-blockers, mineralocorticoid receptor antagonists (MCRAs) and sodium-glucose cotransporter inhibitors (SGLT2) into practice, there is still a high residual risk of unfavorable outcomes in patients with both HFpEF and CHFmrEFV, CHFrFV. Therefore, therapies using implantable cardioverter-defibrillators (ICDs) and cardiac resynchronisation therapy (CRT) are evolving. The review is based on data from PubMed and Google Scholar databases for the last 5 years.